PET/CT findings and dose distribution during radiotherapy in T1N0M0-T2N0M0 glottic cancer.

IF 0.9 4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Hellenic journal of nuclear medicine Pub Date : 2024-01-01 DOI:10.1967/s002449912710

Yukinori Okada, Tatsuhiko Zama, Tomohiro Itonaga, Ryuji Mikami, Mitsuru Okubo, Shinji Sugahara, Masahiko Kurooka, Motoki Nakai, Koichiro Abe, Mana Yoshimura, Kazuhiro Saito

{"title":"PET/CT findings and dose distribution during radiotherapy in T1N0M0-T2N0M0 glottic cancer.","authors":"Yukinori Okada, Tatsuhiko Zama, Tomohiro Itonaga, Ryuji Mikami, Mitsuru Okubo, Shinji Sugahara, Masahiko Kurooka, Motoki Nakai, Koichiro Abe, Mana Yoshimura, Kazuhiro Saito","doi":"10.1967/s002449912710","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the positron emission tomography/computed tomography (PET/CT) findings of T1/T2N0M0 glottic cancer (hereafter referred to as T1/T2) and dose distribution in radiotherapy.Subjects and methods: We retrospectively collected data from patients diagnosed with T1/T2N0M0 glottic cancer who received radiotherapy. The extent of fluorine-18-fluorodeoxyglucose (18F-FDG) accumulation in primary tumors, maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), tumor volume of primary tumors on PET/CT were compared. Furthermore, the tumor identified on PET/CT was incorporated into the radiotherapy plans. A dummy plan (radiation field 6x6cm, prescription point facing the vertebral body, maximum dose ≤107%, T1/T2 66Gy/33 fractions) was developed for three-dimensional conformal radiotherapy, and the dose distribution of primary tumors was calculated.Results: Twenty-nine patients (27 men and two women) were included; their mean age was 67.2±15.0 years. Increased 18F-FDG accumulation in primary tumors was observed on PET/CT in 22/29 (78.5%; T1: 14/21 [67%], T2: 8/8 [100%]) patients. The median SUVmax, TLG, and primary tumor volume were significantly different between T1 and T2 (SUVmax, T1: 4.56 vs. T2: 8.43, P=0.035; TLG, T1: 1.01 vs. T2: 3.71 SUVxmL, P<0.01; primary tumor volume, T1: 0.38mL vs. T2: 0.80mL, P=0.01). At a TLG cut-off value of 3.470, the area under the curve was 0.875, sensitivity was 0.875, and specificity was 0.929 for T1-T2 differentiation. In 20 patients with 18F-FDG accumulation, the minimum radiation dose was significantly different between T1 and T2 (66Gy vs. 64Gy, P<0.01) at the same 66Gy prescription. The minimum radiation dose and primary tumor volume show the correlation value (r=-0.516, P=0.02).Conclusion: In glottic cancer, T1 and T2 can be differentiated by the extent of 18F-FDG accumulation in primary tumors on PET/CT. The minimum radiation dose rate decreases as volume increases.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"27 1","pages":"27-34"},"PeriodicalIF":0.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912710","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the positron emission tomography/computed tomography (PET/CT) findings of T1/T2N0M0 glottic cancer (hereafter referred to as T1/T2) and dose distribution in radiotherapy.

Subjects and methods: We retrospectively collected data from patients diagnosed with T1/T2N0M0 glottic cancer who received radiotherapy. The extent of fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) accumulation in primary tumors, maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), tumor volume of primary tumors on PET/CT were compared. Furthermore, the tumor identified on PET/CT was incorporated into the radiotherapy plans. A dummy plan (radiation field 6x6cm, prescription point facing the vertebral body, maximum dose ≤107%, T1/T2 66Gy/33 fractions) was developed for three-dimensional conformal radiotherapy, and the dose distribution of primary tumors was calculated.

Results: Twenty-nine patients (27 men and two women) were included; their mean age was 67.2±15.0 years. Increased ¹⁸F-FDG accumulation in primary tumors was observed on PET/CT in 22/29 (78.5%; T1: 14/21 [67%], T2: 8/8 [100%]) patients. The median SUVmax, TLG, and primary tumor volume were significantly different between T1 and T2 (SUVmax, T1: 4.56 vs. T2: 8.43, P=0.035; TLG, T1: 1.01 vs. T2: 3.71 SUVxmL, P<0.01; primary tumor volume, T1: 0.38mL vs. T2: 0.80mL, P=0.01). At a TLG cut-off value of 3.470, the area under the curve was 0.875, sensitivity was 0.875, and specificity was 0.929 for T1-T2 differentiation. In 20 patients with ¹⁸F-FDG accumulation, the minimum radiation dose was significantly different between T1 and T2 (66Gy vs. 64Gy, P<0.01) at the same 66Gy prescription. The minimum radiation dose and primary tumor volume show the correlation value (r=-0.516, P=0.02).

Conclusion: In glottic cancer, T1 and T2 can be differentiated by the extent of ¹⁸F-FDG accumulation in primary tumors on PET/CT. The minimum radiation dose rate decreases as volume increases.

查看原文本刊更多论文

T1N0M0-T2N0M0声门癌放疗期间的 PET/CT 发现和剂量分布。

目的研究T1/T2N0M0声门癌（以下简称T1/T2）的正电子发射断层扫描/计算机断层扫描（PET/CT）结果以及放疗中的剂量分布：我们回顾性地收集了接受放疗的T1/T2N0M0声门癌患者的数据。比较了 PET/CT 上原发肿瘤的氟-18-氟脱氧葡萄糖（18F-FDG）聚集程度、最大标准化摄取值（SUVmax）、总病灶糖酵解（TLG）和肿瘤体积。此外，还将 PET/CT 上确定的肿瘤纳入放疗计划。为三维适形放疗制定了假计划（辐射野 6x6厘米，处方点朝向椎体，最大剂量≤107%，T1/T2 66Gy/33分次），并计算了原发性肿瘤的剂量分布：共纳入 29 名患者（27 名男性和 2 名女性），平均年龄为 67.2±15.0 岁。22/29（78.5%；T1：14/21 [67%]，T2：8/8 [100%]）例患者的 PET/CT 观察到原发肿瘤中 18F-FDG 累积增加。中位 SUVmax、TLG 和原发肿瘤体积在 T1 和 T2 之间存在显著差异（SUVmax，T1：4.56 vs. T2：8.43，P=0.035；TLG，T1：1.01 vs. T2：3.71 SUVxmL，P18F-FDG 累积），最小放射剂量在 T1 和 T2 之间存在显著差异（66Gy vs. 64Gy，PConclusion）：在声门癌中，T1 和 T2 可以通过 PET/CT 上原发肿瘤的 18F-FDG 累积程度来区分。随着体积的增大，最小辐射剂量率会降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hellenic journal of nuclear medicine 医学-核医学

CiteScore

1.40

自引率

6.70%

发文量

审稿时长

>12 weeks

期刊介绍： The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and cover the scientific and professional interests of physicians, in the field of nuclear medicine and in medicine in general. The journal may publish papers of nuclear medicine and also papers that refer to related subjects as dosimetry, computer science, targeting of gene expression, radioimmunoassay, radiation protection, biology, cell trafficking, related historical brief reviews and other related subjects. Original papers are preferred. The journal may after special agreement publish supplements covering important subjects, dully reviewed and subscripted separately.